BACKGROUND: Anti-tumor necrosis factor (TNF)-α therapies represent a significant innovation in therapy for psoriasis. However, a significant number of psoriasis patients do not respond well to TNF blockers or show an insufficient control of disease activity on a long-term basis. OBJECTIVE/AIM: The aim of this study was to recognize specific clinical factors that could be associated with a non-response to any available TNF blockers in patients with moderate-to-severe plaque psoriasis. MATERIALS AND METHODS: The authors reviewed the medical records of all patients who had started etanercept, infliximab, adalimumab and had achieved a minimum of 24 months follow-up. The authors identified subjects who were not responsive to all available anti-TNF agents, whatever the chronology of their use. RESULTS: A total of 110 patients were retrospectively examined. Thirteen patients were identified as "non-responders" to all available TNF-α blockers. Current smoking at the start of anti-TNF therapy was associated with non-response to TNF blockers. The group of "non-responders" presented a high mean body mass index and a high baseline PASI score with respect to the group of responders. CONCLUSIONS: The data showed that the majority of non-responder patients were smokers, overweight or obese and had a high baseline PASI score. Concomitant arthritis was not significantly associated with non-response.
BACKGROUND: Anti-tumor necrosis factor (TNF)-α therapies represent a significant innovation in therapy for psoriasis. However, a significant number of psoriasispatients do not respond well to TNF blockers or show an insufficient control of disease activity on a long-term basis. OBJECTIVE/AIM: The aim of this study was to recognize specific clinical factors that could be associated with a non-response to any available TNF blockers in patients with moderate-to-severe plaque psoriasis. MATERIALS AND METHODS: The authors reviewed the medical records of all patients who had started etanercept, infliximab, adalimumab and had achieved a minimum of 24 months follow-up. The authors identified subjects who were not responsive to all available anti-TNF agents, whatever the chronology of their use. RESULTS: A total of 110 patients were retrospectively examined. Thirteen patients were identified as "non-responders" to all available TNF-α blockers. Current smoking at the start of anti-TNF therapy was associated with non-response to TNF blockers. The group of "non-responders" presented a high mean body mass index and a high baseline PASI score with respect to the group of responders. CONCLUSIONS: The data showed that the majority of non-responder patients were smokers, overweight or obese and had a high baseline PASI score. Concomitant arthritis was not significantly associated with non-response.
Authors: Richard B Warren; Catherine H Smith; Zenas Z N Yiu; Darren M Ashcroft; Jonathan N W N Barker; A David Burden; Mark Lunt; Kathleen McElhone; Anthony D Ormerod; Caroline M Owen; Nick J Reynolds; Christopher E M Griffiths Journal: J Invest Dermatol Date: 2015-06-08 Impact factor: 8.551
Authors: William R Swindell; Mrinal K Sarkar; Philip E Stuart; John J Voorhees; James T Elder; Andrew Johnston; Johann E Gudjonsson Journal: Clin Transl Med Date: 2015-03-19
Authors: I Y K Iskandar; D M Ashcroft; R B Warren; M Lunt; K McElhone; C H Smith; N J Reynolds; C E M Griffiths Journal: Br J Dermatol Date: 2017-10-19 Impact factor: 9.302
Authors: R B Warren; A Marsden; B Tomenson; K J Mason; M M Soliman; A D Burden; N J Reynolds; D Stocken; R Emsley; C E M Griffiths; C Smith Journal: Br J Dermatol Date: 2018-08-28 Impact factor: 9.302
Authors: Amir Haddad; Tal Gazitt; Ilan Feldhamer; Joy Feld; Arnon Dov Cohen; Idit Lavi; Faten Tatour; Irena Bergman; Devy Zisman Journal: Arthritis Res Ther Date: 2021-01-29 Impact factor: 5.156